Bluebird Bio Inc (BLUE) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bluebird Bio Inc   (NASDAQ: BLUE)

Bluebird Bio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Bluebird Bio Inc in the first quarter 2025?
Due to the lack of equity, it was not possible to calculate Bluebird Bio Inc 's return on equity (ROE) in its first quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change - - - -77.44 % -
Y / Y Net Income Change - 12.93 % - - -
Net Income (TTM) in Millions 139 0 -16 -103 -166
Return On Equity (TTM) - -0.19 % -17.22 % -77.78 % -93.16 %
BLUE's Total Ranking # # # # #
Equity (TTM) in Millions -58 -32 -6 53 131
Seq. Equity Change - - - -59.57 % -32.64 %
Seq. Net Income Change - 240418.97 % - - -

Back to BLUE Management Effectiveness >> BLUE's 5 Years Annual ROE >> Compare BLUE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 



  News about Bluebird Bio Inc Return on Equity ROE

Bluebird Bio’s Bold Restructuring Navigating Financial Waters Towards Profitability,

Bluebird Bio s Strategic Restructuring: A Bold Move Towards ProfitabilityIn the ever-evolving landscape of biotechnology, where rapid advancements are often accompanied by substantial financial hurdles, bluebird bio, Inc. (Nasdaq: BLUE) is taking decisive steps to streamline its operations and pave a pathway to profitability. Located in Somerville, Massachusetts, bluebird bio recently announced a comprehensive restructuring plan designed to optimize its cost structure and position the company for quarterly cash flow break-even by the latter half of 2025.The biotechnology firm, known for its transformative therapies that aim to treat severe genetic diseases, is on a mission to reduce cash operating expenses by a substantial 20% by the third quarter of 2025. This ambitious initiative comes in response to a thorough review of its business model and operational efficiencies. The company s leadership has recognized the need for a renewed focus on fiscal sustainability, especially in light of a staggering cumulative net loss of $161 million reported for the twelve months ending in the first quarter of 2024.



BLUE Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions -32 195 196 374 1,355
Y / Y Equity Change - -0.92 % -47.54 % -72.38 % 5.45 %
Net Income in Millions 0 0 -267 -819 -619
Y / Y Net Income Change - - - - -
Return On Equity - 0.06 % -135.77 % -218.92 % -45.66 %

Back to BLUE Management Effectiveness >> BLUE's 5 Years Annual ROE >> Compare BLUE ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BLUE's' Return on Equity at Yahoo Finance
BLUE's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BLUE's Competitors
Subscribers only: Roe for Bluebird Bio Inc 's Suppliers
Subscribers only: Return On Equity for BLUE's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE

Date modified: 2026-09-26T07:02:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.